Our strategy is to deliver high-quality and affordable generic and branded generic medicines to patients by:
- strengthening our position as a leading non-injectable generics company in the US;
- maintaining our position as a top three generic injectables company in the US and expanding in existing and new markets; and
- maintaining our position as the leading regional player in the MENA and expanding in new emerging markets.
We are delivering our strategy through our key strategic priorities and measuring our performance with relevant key performance indicators (KPIs).
Maximising portfolio opportunities across our markets
We are maximising the potential of our marketed products, leveraging our skilled sales and marketing teams and building on our strong customer relationships.
Develop a differentiated product portfolio by building best-in-class R&D capabilities
We are enhancing our product offering and strengthening our competitive position by investing in our in-house R&D capabilities and external partnerships to develop differentiated products.
Optimise operations and drive efficiencies
We are investing in high-quality manufacturing facilities to improve the efficiency of our processes, while maintaining tight control of overheads, general and administrative and other operating expenses.
Use M&A and capital investment to accelerate organic growth opportunities
We are investing to expand our product portfolio, technological capabilities, geographic reach and manufacturing capacity through capital investment and M&A.
Attract and develop talent across the Group
We are investing in the training and development of our people, while hiring talented new employees to support our future growth plans.